Citadel Advisors
BTTX

Citadel Advisors’s Better Therapeutics, Inc. Common Stock BTTX Stock Holding History

Citadel Advisors’s Portfolio BTTX Stock Details BTTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-300
Closed -$116 – 15536
2023
Q3 		$116 Buy
+300
New +$202 ﹤0.01% 14161
2023
Q2 		– Sell
-100
Closed -$73 – 15511
2023
Q1 		$73 Sell
100
-86,600
-100% -$102K ﹤0.01% 14598
2022
Q4 		$97.1K Sell
86,700
-19,500
-18% -$28.8K ﹤0.01% 11261
2022
Q3 		$187K Buy
+106,200
New +$194K ﹤0.01% 10472

Other funds holding BTTX

CIAS
Capital Investment Advisory Services Raleigh, North Carolina $1.62B AUM 27.01% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
APC
Aspire Private Capital Cornelius, North Carolina $484M AUM 17.28% 1-Year Est. Return

Citadel Advisors's BTTX Position: Q1 2024 in Review

Citadel Advisors sold out of Better Therapeutics, Inc. Common Stock (BTTX) in Q1 2024, closing a stake of 216,165 shares — an estimated $42.2K sold.

Citadel Advisors first reported a position in BTTX in Q4 2021 and held it in 4 quarters. The position peaked at $59K in Q4 2021. 3 funds tracked by Wall St. Rank hold BTTX as of Q1 2024.

  • Citadel Advisors reported no remaining Better Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Citadel Advisors sold 216,165 Better Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $42.2K.
  • Citadel Advisors first reported a position in Better Therapeutics, Inc. Common Stock in Q4 2021 and held it in 4 quarters.
  • Citadel Advisors's Better Therapeutics, Inc. Common Stock position peaked at $59K in Q4 2021.
  • 3 funds tracked by Wall St. Rank held Better Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Citadel Advisors's 13F filing for Q1 2024, filed 15 May 2024.